IDEAS home Printed from https://ideas.repec.org/a/bla/ecaffa/v45y2025i3p461-478.html

Societal value and health economic benefits of GLP‐1 drugs in the United States

Author

Listed:
  • Frederik Cyrus Roeder
  • Emil Panzaru

Abstract

This article provides an overview of the health economics of glucagon‐like peptide‐1 (GLP‐1) receptor agonists in the United States based on a selection of the key literature, with some comparison references to cost‐effectiveness in the United Kingdom. It discusses the potential health‐care cost savings and societal benefits of products such as semaglutide (Ozempic/Wegovy), followed by current pricing trends and coverage, concluding with methodological and policy implications. To correctly consider the greater positive effects of GLP‐1 agonists, standard methods of assessment must go beyond list prices and balance cost‐containment, equity, and access while preserving competition and choice in the health‐care market.

Suggested Citation

  • Frederik Cyrus Roeder & Emil Panzaru, 2025. "Societal value and health economic benefits of GLP‐1 drugs in the United States," Economic Affairs, Wiley Blackwell, vol. 45(3), pages 461-478, October.
    • Handle: RePEc:bla:ecaffa:v:45:y:2025:i:3:p:461-478
    DOI: 10.1111/ecaf.70011
    as

    Download full text from publisher

    File URL: https://doi.org/10.1111/ecaf.70011
    Download Restriction: no
    File URL: https://libkey.io/10.1111/ecaf.70011?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:bla:ecaffa:v:45:y:2025:i:3:p:461-478. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Wiley Content Delivery (email available below). General contact details of provider: http://www.blackwellpublishing.com/journal.asp?ref=0265-0665 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.